I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

Please select preferred method for the calendar invite

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Welcome to

MEDICALLY

Roche’s International Medical Congress Platform. Medical congresses bring together healthcare professionals to share information about their specialties. MEDICALLY compiles and shares Roche and Genentech's congress materials from medical congresses around the world.

Preview the latest congresses

Browse information about latest congresses and view the congress calendar

Sign up or login to unlock the full suite of MEDICALLY features

Sign up or login to unlock the full suite of MEDICALLY features

November 19 - November 23, 2024 / Vancouver, Canada
AMP 2024

Sign up or login to unlock the full suite of MEDICALLY features

November 19 - November 20, 2024 / Chicago, USA / Virtual (Hybrid)
ASGCT Breakthroughs 2024
No result found

Preview the latest medical materials

Take a look at materials from the latest medical congresses

Sign up or login to unlock the full suite of MEDICALLY features

Nov 24 / Roche and Genentech
Global Real-World Clinical and Anatomical Outcomes With Faricimab▼ in Treatment-Naïve Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema From a Multi-Country Prospective Non-Interventional Study: The VOYAGER Study
This presentation describes the results of an interim analysis of treatment-naïve patients (baseline to month 6) receiving faricimab▼ in the innovative real-world VOYAGER study. The global VOYAGER study investigates the real-world effectiveness, safety, treatment patterns and anatomical features affecting vision outcomes with faricimab▼ in patients with nAMD and DME on a global level. Treatment-naive eyes achieved visual gains and anatomic improvements during the follow-up period.

Sign up or login to unlock the full suite of MEDICALLY features

Nov 24 / Roche and Genentech
Faricimab▼ for Polypoidal Choroidal Vasculopathy: Week 16 Results From the Phase 3b/4 SALWEEN Trial
This presentation describes the week 16 (interim) results of the phase 3b/4 SALWEEN study. SALWEEN is investigating the efficacy, safety and durability of faricimab▼ in patients with polypoidal choroidal vasculopathy (PCV) from Asian countries, a subtype of nAMD which is highly prevalent in Asia and a population underrepresented in the phase 3 TENAYA/LUCERNE trials. Interim efficacy and safety results have demonstrated robust improvements in vision and anatomy, and complete closure and inactivation of polypoidal lesions in the majority of patients. Faricimab▼ was well tolerated and consistent with the known safety profile of faricimab▼.

Sign up or login to unlock the full suite of MEDICALLY features

Nov 19 / Roche
Genomics Annotation and Interpretation in Somatic Oncology with a Highly Structured Data Model
navify® Mutation Profiler provides an automated cloud-based solution to streamline the process of annotating, interpreting and reporting variants from next-generation sequencing (NGS) somatic oncology test results. Ephesus is an internal web application enabling expert curation for construction of a robust knowledgebase of NGS biomarkers to support the mutation profiler. In this study, we assessed the reporting capability of Ephesus/navify Mutation profiler by querying somatic variants in ~170K real cancer cases from the AACR GENIE® (v16.1) project, and comparing against several public knowledgebases. Ephesus/navify Mutation Profiler outperformed the other knowledgebases in having the highest number of interpreted cases and biomarker profiles.
No result found

Join an ever-growing community

Sign up using LinkedIn or register via email.

Signing up allows you to access exclusive content and personalize your feeds so you see only what’s relevant to you and your practice.